14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
NVS vs PFE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Pfizer Inc. (PFE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NVS carries a Unified Composite Score of 42.2/100 (HOLD) at $159.20 (16.1x Forward P/E, 34.0% operating margin), whereas PFE carries 52.3/100 (HOLD) at $28.45 (9.8x Forward P/E, 29.1% operating margin).
Composite vs. Pillar Nuance: While PFE currently prints a higher short-term Unified Composite Score (52.3/100 HOLD vs. NVS 42.2/100 HOLD), NVS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 29.1% operating margin) and revenue trajectory (+4.7% vs. -0.4% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs PFE. Trailing 12-month operating profitability (NVS 34.0% vs PFE 29.1%) and valuation multiples (NVS 16.1x vs PFE 9.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - General value chain with $303.1B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment41.2% of Rev ($16.7B)
90D Engineering Disclosures0 Published
PFE Moat ProfileScale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $164.7B market capitalization and 29.1% operating margin.
OpEx & R&D Reinvestment45.8% of Rev ($29.1B)
90D Engineering Disclosures0 Published
Investor FAQ NVS vs PFE Key Questions & Quantitative Answers
As of Nov 17, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Pfizer Inc. (PFE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NVS carries a Unified Composite Score of 42.2/100 (HOLD) at $159.20 (16.1x Forward P/E, 34.0% operating margin), whereas PFE carries 52.3/100 (HOLD) at $28.45 (9.8x Forward P/E, 29.1% operating margin). Composite vs. Pillar Nuance: While PFE currently prints a higher short-term Unified Composite Score (52.3/100 HOLD vs. NVS 42.2/100 HOLD), NVS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 29.1% operating margin) and revenue trajectory (+4.7% vs. -0.4% YoY).
NVS leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with PFE at -0.4% YoY revenue growth and -9.7% YoY earnings growth on $63.6B TTM revenue (74.9% gross margin, 29.1% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $63.6B for PFE. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 45.8% of Rev ($29.1B) (0 disclosures) for PFE.
PFE screens cheaper on headline valuation multiples. NVS trades at 16.1x Forward P/E, 30.6x Trailing P/E, 3.82x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas PFE trades at 9.8x Forward P/E, 41.3x Trailing P/E, 8.83x PEG, and 3.5x EV/Revenue (18.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus PFE (4.5% ROE) capital efficiency.
In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 26% Vol realized risk). By comparison, PFE carries 27.7% implied volatility (33rd %ile, Balanced (25th–60th %ile)), a 0.62x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.18β · 24% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.